Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Envafolimab + Tegafur-Gimeracil-Oteracil as second-line therapy for advanced pancreatic cancer (Phase II, single-arm)
ChiCTR2200060760Phase 2Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, envafolimab and tegafur-gimeracil-oteracil in pancreatic cancer (PC), sponsored by Fujian Provincial Hospital. Primary endpoint: Progression-Free Survival. Started Jun 2022; status: recruiting.
02
Drugs
surufatinibenvafolimabtegafur-gimeracil-oteracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2200060760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060760.